Biopharma news, November 17, 2026
4 stories
In this digest: Approval 3 · M&A 1
Top stories
Cosentyx FDA Approval for PMR
The FDA approved Cosentyx 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering. In the Phase III REPLENISH trial, sustained remission at week 52 was 40.5% with Cosentyx 150 mg versus 20.5% with placebo, following a 24-week steroid taper. Serious adverse events occurred in 15.9% and 14.2% of the respective groups; a fatal cryptococcal meningitis case occurred in a Cosentyx-treated patient.
Source types: Press release
FDA Approves Pebrilzo Biosimilar
The FDA approved Biocon's Pebrilzo, a Perjeta biosimilar, for use in specified combination regimens for HER2-positive early and metastatic breast cancer.
Read more about FDA Approves Pebrilzo Biosimilar
A settlement and license agreement with Genentech permits the earliest licensed U.S. launch in the third quarter of 2028. An EMA committee previously recommended European marketing authorization. Pebrilzo is Biocon's fifth FDA-approved oncology biosimilar. Its boxed warnings include left ventricular dysfunction and embryo-fetal toxicity.
Source types: Press release
J&J to Acquire Ollin
Johnson & Johnson announced the acquisition of Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in milestones, obtaining OLN324 and OLN102.
Read more about J&J to Acquire Ollin
Blackstone will provide $750 million to support OLN324 phase 3 development in exchange for a single-digit sales participation and regulatory and sales milestones. Two global phase 3 trials of OLN324 in wet age-related macular degeneration began in September 2026; a diabetic macular edema phase 3 trial is also planned.
Source types: Press release · News article
News in brief
FDA Approves WILSERDLY Combination
Read more about FDA Approves WILSERDLY Combination
The FDA approved WILSERDLY plus everolimus for eligible adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following endocrine therapy. In the Phase III evERA study, the combination reduced the risk of progression or death by 62% versus standard endocrine therapy plus everolimus in the ESR1-mutated population. The FDA is reviewing WILSERDLY for adjuvant treatment of early-stage breast cancer, with a decision due November 30, 2026.
Source types: Press release · News article
Sources are available to Gosset users. Log in to see them.
All digests
- November 16, 2026 3 stories
- November 15, 2026 4 stories
- November 14, 2026 5 stories
- November 13, 2026 5 stories
- November 12, 2026 10 stories
- November 11, 2026 10 stories
- November 10, 2026 10 stories
- November 9, 2026 10 stories
- November 8, 2026 9 stories
- November 7, 2026 7 stories
- November 6, 2026 10 stories
- November 5, 2026 10 stories